Leptin therapy in animal models shows promise for type 1 diabetes

Mar 24, 2010

Using leptin alone in place of standard insulin therapy shows promise in abating symptoms of type 1 diabetes, UT Southwestern Medical Center researchers report.

UT Southwestern researchers, using mouse models, found that leptin administered instead of showed better management of blood-sugar variability and lipogenesis, the conversion of simple sugars into fatty acids. Leptin is a hormone produced by and involved in the regulation of body weight.

Dr. Roger Unger, professor of internal medicine at UT Southwestern, led the study whose findings are available online and in a future issue of the .

Insulin treatment has been the gold standard for (insulin-dependent diabetes) in humans since its discovery in 1922. Dr. Unger's laboratory found that insulin's benefit resulted from its suppression of glucagon, a hormone produced by the pancreas that raises blood sugar levels in healthy individuals.

"Insulin cells are destroyed in people with type 1 diabetes, however, and matching the high insulin levels needed to reach glucagon cells with insulin injections is possible only with amounts that are excessive for other tissues," said Dr. Unger, senior author of the latest study. "Peripherally injected insulin cannot accurately duplicate the normal process by which the body produces and distributes insulin."

People on insulin therapy tend to experience large swings in blood-sugar levels, said Dr. Unger. Other studies have shown that frequent blood-sugar variation complicates the symptoms of type 1 diabetes, which affects about 1 million people in the U.S.

Benefits of letpin's glucose-lowering action appear to involve the suppression of glucagon. Normally, glucagon is released when the glucose level in the blood is low, thanks to supervision by insulin release from neighboring cells. In insulin deficiency situations, however, glucagon levels are inappropriately high and cause the liver to release excessive amounts of glucose into the bloodstream. This action is opposed by insulin, which tells the body's cells to remove sugar from the bloodstream.

"Leptin treatment in the non-obese type 1 diabetic mouse profoundly reduced food intake, which in turn reduced body fat," Dr. Unger said. "And like insulin, leptin suppresses glucagon in the body and helps increase lean body mass."

As a countermeasure to the destruction of their pancreatic islet cells, type 1 diabetics currently must take insulin multiple times a day to metabolize blood sugar, regulate blood-sugar levels and prevent diabetic coma. They also must adhere to strict dietary restrictions.

"We hope the positive results we've had in animals can translate to people living with this disease," Dr. Unger said. " has transformed a uniformly fatal disease into a livable one; however, the regimen for people with type 1 is onerous and symptoms aren't always well controlled. We hope that low-dose insulin combined with leptin will closely mimic the body's normal physiological process."

Explore further: New hope in fight against muscular dystrophy

add to favorites email to friend print save as pdf

Related Stories

Study pinpoints role of insulin on glucagon levels

Apr 07, 2009

April 7, 2009 - Researchers at the Joslin Diabetes Center have shown for the first time that insulin plays a key role in suppressing levels of glucagon, a hormone involved in carbohydrate metabolism and regulating blood glucose ...

Researchers Find Food-free Route to Obesity

Oct 19, 2006

Can people get fat -- and risk debilitating diabetes -- without overeating? The answer may be yes, according to Timothy Kieffer, a University of British Columbia researcher, who has found that imbalance in the action of a ...

Recommended for you

New hope in fight against muscular dystrophy

2 minutes ago

Research at Stockholm's KTH Royal Institute of Technology offers hope to those who suffer from Duchenne muscular dystrophy, an incurable, debilitating disease that cuts young lives short.

Biologists reprogram skin cells to mimic rare disease

18 hours ago

Johns Hopkins stem cell biologists have found a way to reprogram a patient's skin cells into cells that mimic and display many biological features of a rare genetic disorder called familial dysautonomia. ...

User comments : 0